- Thermo Fisher forms part of the Life Sciences and Tools Industry.
- With more vaccination, COVID diagnostic sales have fallen in the second quarter compared to the prior one, but thanks to higher base revenues, the company has actually managed to exhibit growth.
- I go deeper into finances to understand how the company has been able to increment margins despite the rising costs of revenues and operating expenses.
- Pushing the margins rationale further, the Life Sciences play has grown in a more efficient way compared to another large peer.
- I start with some insightful market reactions after Merck revealed progress on its oral anti-COVID tablet.
For further details see:
Thermo Fisher: Definitely Helped By COVID Testing But There Is More